STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more

The US biotech industry is facing a problem with China, having spent $60 billion on Chinese molecules in the first three months of 2026. President Trump bought $680,000 in Eli Lilly stock as his agencies made decisions benefiting the company. This has raised questions about partnering with Chinese firms and potential conflicts of interest.